by Raynovich Rod | Feb 28, 2019 | Biopharmaceuticals
Update-2…Biotech rally Friday and Gene Therapy stocks One clue to the stealth rally on Friday is this article in Barron’s published Saturday (? hmmm) Why Big Pharma is Diving into Gene Therapy If you cannot access this article and are not a subscriber go...
by Raynovich Rod | Feb 25, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs...
by Raynovich Rod | Feb 14, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: GenMark (GNMK) Soars on Q4 and Full Year 2018 Results Revenues of $70.8M were 35% over 2017 Results Q4 Revenues were $19.4M an increase of 21% over prior year. ePlex Revenues for Q4 were 412.1M an increase of 110% over prior year. Loss per share was reduced...
by Raynovich Rod | Feb 10, 2019 | Biopharmaceuticals
Biotech Stocks Hold Despite Last Thursday’s Sell-Off All in the Technicals For Now, Large Caps Look Steady Biotech ETFs lost momentum last week but held near term support near the 20 Day moving average. Now that most companies have reported we should not expect...
by Raynovich Rod | Feb 4, 2019 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Clinical Diagnostics and Tools
Update 2/7/19 Mid-Day Trading : Risk Off Day The market is trending down with all major indices in the red and the XBI $81.96 down 2.75%. We sold our position in the XBI yesterday at $83+. Array (ARRY) continues to run up at $21.60. Hot stock MacroGenics (MGNX) cooled...
by Raynovich Rod | Jan 24, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update ….Jan 30 2:45p EST …FED to be Patient and Policy Stance is Appropriate FED to “wait and see” before raising rates-stocks soar. FED-“US Economy in a good place” NASDAQ up 2%, DOW up 1.73%, S&P up 1.53% XLV up 1.27%, IBB...
by Raynovich Rod | Jan 17, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update-2 1/21/19…Heads Up Red Futures Growth worries return-Asian Stocks down IMF Lowers Global Growth-Poor Performance for Europe Biotech rally could stall Update-1 1/20/19…XBI at $83.38 approaching November resistance at $85 Barron’s 2019...
by Raynovich Rod | Jan 9, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update 1/14 After close: Biopharmas on the weak side from drug pricing politics. Both parties focused on pharmaceutical drug prices. IBB at $107.17 down 1.69% ; XBI at $80.12 down 2.29%. Red screen for Mid-Caps; BLUE BPMC NKTR all up a tad. Update 1/13 10:30P Sunday-...
by Raynovich Rod | Jan 8, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1…1/21/19 Liquid Biopsy I attended a Panel Session on Cancer Liquid Biopsy and although progress is being made on molecular diagnostics there are no newsworthy breakthroughs nor actual data showing a hard timeline. Here is an article from BIO 2016. There...
by Raynovich Rod | Jan 7, 2019 | Biopharmaceuticals
1/7/19 …After Close: Most Mid-Caps held gains but check AH trading Selected Winners today: AGIO 8.7%, ALNY 8.75%, ARRY 8.85%, BLUE 6.67%, BPMC 14.1%, NKTR 7.83%, SGEN 5.68%, ICPT 7.28%, XBI 5.97% (closed at highs. $79.50). Many of these mid-caps are still at low...
